Abcam, ab257357, Human ARID2 knockout HeLa cell lysate

Size: 1Kit
ARID2 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon2.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon2.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-ARID2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
ARID2 also known as AT-rich interactive domain-containing protein 2 is a component of the SWI/SNF chromatin remodeling complex. It has a molecular mass of approximately 183 kDa. ARID2 is expressed in various tissues with high levels found in the liver kidney and testis. In the cell nucleus it functions as a DNA-binding protein playing a role in modulating chromatin structure through its interaction with other chromatin-associated proteins.
Biological function summary
ARID2 contributes to regulating gene expression by remodeling chromatin allowing transcription factors access to DNA. It acts as a part of the PBAF subtype of the SWI/SNF complex which includes proteins like BRG1 and BAF200. This complex influences transcriptional activation and repression aiding the regulation of genes important for cellular differentiation and development. Loss or mutation of ARID2 affects normal biological processes indicating its role in ensuring proper cellular function.
Pathways
ARID2 plays a role in the RAS signaling and the Hedgehog signaling pathways. It interacts with proteins such as BAF155 and BAF170 which are essential for recruiting and assembling the PBAF complex on chromatin. These pathways are critical for cellular proliferation and differentiation ensuring that cells respond accurately to signals which is vital for maintaining tissue homeostasis and proper organismal development.
ARID2 mutations are linked to hepatocellular carcinoma and malignant melanoma. These mutations are associated with abnormalities in chromatin remodeling that lead to transcriptional dysregulation. The target is also connected to proteins like BRD9 and BRD7 within the context of cancer which are involved in tumor suppression. Alterations in ARID2 might contribute to the progression and aggressiveness of these cancers by disrupting normal chromatin dynamics and gene expression patterns.